Takeda's Orzeyful gets Japan approval for narcolepsy type 1
Takeda Pharmaceutical's Orzeyful (oveporexton) is approved in Japan as the first and only medicine to treat the underlying cause of narcolepsy type 1, marking its third major regulatory approval worldwide.